Aunque no es algo que se espere en absoluto de los investigadores de ICREA, a veces dan con algo que promete convertirse en una potente tecnología nueva pero parece imposible ir más allá en su desarrollo sin una inversión significativa de tiempo y dinero. En estos casos, muchos optan por estudiar la creación de una SPIN OFF.
List of spin off companies
LuxQuanta Technologies SL
Supported by ICFO and ICREAview details
Entrepreneur: ICREA Research Professor Valerio Pruneri
Born in May 2021
LuxQuanta was born in May 2021 as a spin-off from ICFO, and after being incubated for over 4 years, with the mission of developing Quantum Key Distribution (QKD) systems. These systems can distribute cryptographic keys between users with the highest level of security as they rely on the unique properties of quantum physics instead of mathematical algorithms.
LuxQuanta uses a novel QKD technology capable of providing high-performance and cost-effective quantum cryptography solutions, easy to integrate into existing optical network infrastructures while capable of delivering a quantum-safe layer of security on top of traditional crytographic techniques.
From its headquartes in Barcelona and with solid Spanish shareholders foundations, LuxQuanta want to deliver ultra-secure data encryption and communications to all European Union's governmental institutions, financial sectors, data centers and private telecommunication network providers for years to come.
Supported by the Centre de Regulació Genòmica (CRG) and ICREA.view details
Entrepreneur: ICREA Research Professor Toni Gabaldón.
Born in September 2017.
Microomics SL its a Biotech spin-off of the CRG (Centre for Genomic Regulation) specialized in microbiome analysis, being the fist biotech in the national territory that focuses in metagenomics solutions. We are supported by the CRG (Centre for Genomic Regulation) and allowed to grow within the exciting environment of the Barcelona Biomedicine Research Park (PRBB). Our business strengths rely on high technical expertise and top-notch research facilities, combined with attractive strategic partnerships and academic collaborations. Our mission is to bring advanced scientific expertise to provide practical solutions to customer and the society as an alternative and innovative approach to new and traditional questions in Biomedicine, Health-Care, Energy, Agrifood, including animal and plan breeding, Consumer Goods Industry and Environmental sectors. We transform metagenomic data into knowledge contributing to society through sustainable growth and improved health and wellbeing.
Supported by the Universitat de Barcelona (UB) and ICREA.view details
Entrepreneur: ICREA Research Professor Xavier Barril
Born in October 2011.
Minoryx Therapeutics develops treatments for Inborn Errors of Metabolism, a group of rare diseases of genetic origin affecting 3,700 newborns every year in Europe. Such diseases are life threatening and highly debilitating, usually with neurological manifestations and affect most severely the pediatric population. The social and economic impact of these diseases cannot be overstated and, with 90% of cases lacking curative treatments, there is a high unmet medical need. Minoryx develops new drugs to improve both the quality of life and life expectancy of the patients.
Minoryx has developed SEE-Tx (Site-directed Enzyme Enhancement Therapy), a technological platform that incorporates computational methods developed in the Barril’s lab at Barcelona University. SEE-Tx enables us to develop a new generation of drugs: the non-competitive pharmacological chaperones, which recover the functionality of mutated proteins, thus attacking the root of the disease. We have discovered non-competitive pharmacological chaperones in a range programs, which are at various stages of preclinical research.
Supported by the Universitat Pompeu Fabra, Universitat Politècnica de Catalunya, Hospital Clínic de Barcelona and ICREA.view details
Entrepreneur: ICREA Research Professor Miguel Á. González Ballester.
Born in September 2019.
MiWEndo Solutions develops MiWEndo, a novel medical device that applies microwave imaging technology to colonoscopy. MiWEndo aims to contribute to improving prevention and diagnosis of colorectal cancer, as well as serving as an exploratory tool to increase the scientific knowledge about this type of cancer. MiWEndo automatises the detection of polyps and raises an alarm when one is detected. Furthermore, it augments the field of view to 360º and provides quantitative tissue classification, without any modification to current clinical procedures.
Colon cancer is a highly prevalent and devastating disease. The current push for screening programs worldwide has led to an increase in colonoscopy procedures. Detection of polyps in these explorations highly relies on the experience of the clinical expert, and is therefore subject to subjectivity and fatigue. MiWEndo aims at providing a novel valuable tool to the clinician, thus contributing to reduce the number of missed polyps in colonoscopies.
The global market for colonoscopy is approximately 1550M€, with a yearly increase of 5%. The main target markets for MiWEndo, at present, are Europe, USA and Japan. MiWEndo is a patented device, and it is safe, complementary to existing colonoscopes and low-cost. MiWEndo will lead to increased polyp detection rates and better decision support, by providing more information about the malignancy of the tissue. It will also reduce time and cost, in terms of faster explorations, less repeated colonoscopies, reduced patient preparation time and earlier detection and treatment of colorectal cancer.
 González Ballester et al. (2017), European patent no. EP3195786A1.
 Guardiola et al. (2018), Medical Physics, vol. 45(8), 3768-3782.
 Guardiola et al. (2019), IEEE Transactions on Antennas and Propagation, vol. 67(8), 4968-4977.